Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 3/20 | 0.62 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.57 |
| ▸ | FLT1 | P17948 | 5/20 | 0.57 |
| ▸ | FLT4 | P35916 | 5/20 | 0.57 |
| ▸ | KDR | P35968 | 5/20 | 0.57 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.57 |
| ▸ | FGFR4 | P22455 | 4/20 | 0.57 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.57 |
| ▸ | SRC | P12931 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 6/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.53 |
| ▸ | EHMT2 | Q96KQ7 | 3/20 | 0.44 |
| ▸ | EHMT1 | Q9H9B1 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5493929 | 0.94 | ENPP1 (0.64) | ENPP1FGFR1FLT1FLT4KDR | |
| SCHEMBL4427378 | 0.86 | FGFR1 (0.55) | ENPP1FGFR1FLT1FLT4KDR | |
| SCHEMBL4383833 | 0.81 | ENPP1 (0.64) | ENPP1FGFR1FLT1FLT4KDR | |
| SCHEMBL1015576 | 0.80 | ENPP1 (0.79) | ENPP1FGFR1FLT1FLT4KDR | |
| SCHEMBL30864338 | 0.80 | ENPP1 (0.79) | ENPP1FGFR1FLT1FLT4KDR | |
| SCHEMBL1013051 | 0.80 | ENPP1 (0.79) | ENPP1FGFR1FLT1FLT4KDR | |
| SCHEMBL31620798 | 0.80 | ENPP1 (0.79) | ENPP1FGFR1FLT1FLT4KDR | |
| SCHEMBL3955512 | 0.79 | ENPP1 (0.65) | ENPP1FGFR1FLT1FLT4KDR | |
| SCHEMBL2921945 | 0.79 | ENPP1 (0.65) | ENPP1FGFR1FLT1FLT4KDR | |
| SCHEMBL13299050 | 0.79 | ENPP1 (0.86) | ENPP1FGFR1FLT1FLT4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939866-B2 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2005-09-06 | — | — | US | disclosed |
| US-20040044015-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044015-A1 | Quinazoline derivatives | NQO2, NRAS, TOP1 | ENPP1 3445/4885FGFR1 3297/4885FLT1 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.